Severe Asthma.

Slides:

Advertisements

Similar presentations

Treatments for Asthma Ghazaleh Ebrahimnejadalamaki, Gea Panić, Natali Surkic, Romina Isip [1] PHM142 Fall 2015 Coordinator: Dr. Jeffrey Henderson Instructor:

Advertisements

Biologics in Asthma—The Next Step Toward Personalized Treatment

Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis—PRACTALL document of the European Academy of Allergy and.

NEW TREATMENT OPTIONS IN ASTHMA

Fig. 1. Pathological mechanisms of asthma

Moderate-to-Severe Asthma Management

Anti-IgE effect of the mAb omalizumab

Clinical Trials in IBD.

Evolution of Treatment Strategies Targeting IL-23 for Psoriasis

Why Gene Therapy for Hemophilia?

Diagnosis, Evaluation, and Therapy for Severe Refractory Eosinophilic Asthma.

Allergy Testing in Children

Chronic Rhinosinusitis

Clinical Review.

Stepping Up Asthma Control for Effective Management

Atopic Dermatitis Treatment Landscape

Adapted from Catley et al, Pharm Therap 2011

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Chronic Idiopathic Urticaria

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Addressing Disease Burden in Asthma

Asthma and Atopic Comorbidities

Postpartum Depression

Next-Gen Psoriasis Therapies:

Case Studies in Unresectable Hepatocellular Carcinoma

Gene Therapy: Past, Present, and Future

Emerging Atopic Dermatitis Treatments:

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Ask the Experts.

Current application of exhaled nitric oxide in clinical practice

Perspectives on the Impact of Inflammation in OA

Advancing the Treatment of IBD With Biologics

When Is Biologic Therapy Appropriate for HS?

Improving Outcomes in Psoriatic Arthritis

The Evolving Treatment Landscape in Atopic Dermatitis

Oral Prostanoids and PAH

Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.

Advancing Patient Care in RA

Advances in Severe Asthma Management

Guide to Atopic Dermatitis

Challenges in Severe Asthma

Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis—PRACTALL document of the European Academy of Allergy and.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Understanding the Updated Guidelines for ALK Testing in NSCLC

Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison William Busse, MD, Geoffrey Chupp,

Achieving Asthma Control

Patient Questions and Expert Answers in Psoriasis:

Daniel L. Hamilos, MD Journal of Allergy and Clinical Immunology

Severe Asthma and Comorbidities

Optimizing Joint Health in Hemophilia

Diagnosis, Evaluation, and Therapy for Severe Refractory Eosinophilic Asthma.

Update on the Management of Atopic Dermatitis

Anti-interleukin 13 for asthma: stick or twist?

Novel Concepts in the Management of RCC

Biologics and biomarkers for asthma, urticaria, and nasal polyposis

From Adjuvant to Metastatic in Melanoma

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

HAE Prophylaxis.

Checkpoint Inhibitors in First-Line Advanced NSCLC

Peanut Allergy Immunotherapy

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Pathophysiologic Targets of Allergic Asthma

GINA Pocket Guide Difficult to treat and severe asthma in adults and adolescents V2.0 April 2019 This slide set is restricted for academic and educational.

Updates in Progressive MS

Albert Y. Wu, MD, Sanjiv Sur, MD, J. Andrew Grant, MD

The Asthma Treatment Gap

Exploring the Role of Biologics in Reducing Oral Corticosteroid Use in Severe Asthma.

Foundations of Asthma.

Foundations of Asthma.

Presentation transcript:

Severe Asthma

This program will include a discussion of investigational agents not approved by the FDA for use in the US.

Severe Asthma: Overview

How Is Severe Asthma Defined? ERS/ATS Guidelines

How Is Uncontrolled Asthma Defined? ERS/ATS Guidelines

How Is Severe Asthma Defined? GINA Guidelines

Evolution of Asthma Classification

T2-Mediated Inflammation

Non-T2-Mediated Inflammation

Asthma Phenotypes

Severe Asthma Phenotyping

Proposed Asthma Phenotypes

Asthma Endotypes

Selected Asthma Endotypes

Potential Application of Asthma Biomarkers

Ideal Biomarker Characteristics

Severe Asthma Biomarkers

Biologics for Severe Asthma

Blocking the IgE Allergic Cascade

Omalizumab

Anti-IL-5 Therapy in Eosinophilic Asthma

Mepolizumab

Mepolizumab Phase 3 Study Results

Reslizumab

Reslizumab Phase 3 Study Results

Benralizumab

Benralizumab Phase 3 Study Results

Anti-IL-4/IL-13 Therapy

Inhibiting IL-13 in Severe Asthma

Dupilumab Phase 2b Study

Dupilumab Phase 3 Study

Moving Toward Precision Medicine in Severe Asthma

Abbreviations

Abbreviations (cont)